The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

Flint A, Kapitza C, Hindsberger C, Zdravkovic M

Advances in therapy17 Feb 2011Cited by 70 (Europe PMC)

PMID21340616DOI10.1007/s12325-010-0110-xPepBankPUB-21340616

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial plasma glucose decreased significantly after all three liraglutide doses compared with placebo (P<0.001).
In plain wordsIn adults with type 2 diabetes, liraglutide at all three doses lowered blood glucose after a meal compared with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose (PPG)
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6, 1.2 and 1.8 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
PPG levels significantly decreased (P<0.001) after all three liraglutide doses when compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the postprandial glucose decrease with liraglutide versus placebo was also apparent when corrected for baseline (incremental excursions).
In plain wordsIn adults with type 2 diabetes, liraglutide still lowered the rise in blood glucose after a meal compared with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose incremental excursions
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6, 1.2 and 1.8 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
This decrease was also apparent when corrected for baseline (incremental excursions)
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 0.6 mg showed only a trend to decrease the average incremental glucose increase over 5 hours versus placebo (P=0.082).
In plain wordsIn adults with type 2 diabetes, liraglutide 0.6 mg showed only a trend, not a clear drop, in one glucose measure after a meal.
Peptide
Liraglutide
Outcome
No significant changeIncremental glucose iAUC(0-5 h)/5 hours at 0.6 mg
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
with the exception of average incremental increase calculated as area under the concentration curve (AUC) over the fasting value from time zero to 5 hours (iAUC (0-5 h)/5 hours) after liraglutide 0.6 mg, where there was a trend to decrease (P=0.082).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting plasma glucose decreased significantly at all three liraglutide dose levels compared with placebo (P<0.001).
In plain wordsIn adults with type 2 diabetes, all three liraglutide doses lowered fasting blood glucose compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose (FPG)
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6, 1.2 and 1.8 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
In addition, FPG levels significantly decreased at all three liraglutide dose levels when compared to placebo (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting insulin increased significantly with liraglutide versus placebo at all doses (P<0.001).
In plain wordsIn adults with type 2 diabetes, liraglutide raised fasting insulin levels compared with placebo at all doses.
Peptide
Liraglutide
Outcome
IncreaseFasting insulin
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.6, 1.2 and 1.8 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
Fasting and postprandial insulin levels significantly increased with liraglutide versus placebo at all doses studied (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial insulin increased significantly with liraglutide versus placebo at all doses (P<0.001).
In plain wordsIn adults with type 2 diabetes, liraglutide raised insulin levels after a meal compared with placebo at all doses.
Peptide
Liraglutide
Outcome
IncreasePostprandial insulin
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.6, 1.2 and 1.8 mg/day · 3 weeksAs given in this study (human).
Source sentences
Summary
Fasting and postprandial insulin levels significantly increased with liraglutide versus placebo at all doses studied (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061606
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, gastric emptying during the first hour after a meal was significantly delayed at the two highest liraglutide doses versus placebo.
In plain wordsIn adults with type 2 diabetes, the two higher liraglutide doses slowed stomach emptying after a meal, compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseGastric emptying during the first hour postmeal
Study
n = 18
Comparator
Placebo
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
two highest doses (1.2 and 1.8 mg/day) · 3 weeksAs given in this study (human).
Source sentences
Summary
A significant delay in gastric emptying during the first hour postmeal was observed at the two highest liraglutide doses versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighteen subjects with type 2 diabetes, aged 18-70 years, with a body mass index of 18.5-40 kg/m(2) and HbA(1c) of 7.0%-9.5% were included in this single-centre, randomized, placebo-controlled, double-blind, two-period, cross over trial.
Summary · context
A meal test was performed at steady-state liraglutide/placebo doses of 0.6, 1.2, and 1.8 mg/day.
Report a problemFND-2134061607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01517555

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 18Oct 2006 to May 2007

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.